论文部分内容阅读
目的评价应用孟鲁司特联合沙美特罗替卡松粉吸入剂治疗咳嗽变异性哮喘(CVA)对肺功能指标、呼出气一氧化氮(FeNO)的影响和疗效。方法 80例CVA患者,随机分为治疗组和对照组,各40例。治疗组给予孟鲁司特联合沙美特罗替卡松粉吸入剂治疗,对照组单纯使用沙美特罗替卡松粉吸入剂治疗。对两组临床治疗效果、肺功能指标及FeNO进行比较。结果治疗组总有效率100%高于对照组85%(P<0.05);用力呼出气量为25%~75%肺活量时的平均流量与用力肺活量的比值(FEF25%~75%/FVC)、FeNO明显改善,与对照组比较,差异有统计学意义(P<0.05)。结论孟鲁司特联合沙美特罗替卡松粉吸入剂治疗CVA疗效显著,可明显改善气道高反应性及减轻气道炎症。
Objective To evaluate the effect and efficacy of montelukast combined with salmeterramide and fluticasone powder inhaler on pulmonary function parameters, exhaled nitric oxide (FeNO) and cough variant asthma (CVA). Methods Eighty patients with CVA were randomly divided into treatment group and control group, 40 cases each. The treatment group was treated with montelukast plus salmeterrel hydrochloride inhalation, and the control group received salmeterol and fluticasone propionate inhalation alone. The clinical efficacy, lung function and FeNO were compared between the two groups. Results The total effective rate in the treatment group was 100% higher than that in the control group (P <0.05). The ratio of average flow volume to forced vital capacity (FEF25% -75% / FVC) when forced exhaled volume was 25% -75% Compared with the control group, the difference was statistically significant (P <0.05). Conclusion Montelukast combined with salmeterol and fluticasone powder inhalation for the treatment of CVA has significant curative effect, can significantly improve airway hyperresponsiveness and reduce airway inflammation.